Claim0556f2435074361146313cba4fa7ed59c0e6fed007017137283abfbaf18e543a·My Arguments

In the SELECT randomized controlled trial — 17,604 adults with obesity and established cardiovascular disease but no diabetes, followed for a mean of ~40 months — once-weekly semaglutide reduced major adverse cardiovascular events (CV death, non-fatal MI, non-fatal stroke) by 20% versus placebo, with concordant reductions in renal outcomes and progression to diabetes.

Evidence (1)

SELECT trial summary
20% MACE reduction over ~40 months in 17,604 non-diabetic adults with obesity and established CVD.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11544414/

Respond to this claim on Isonomia

Build or challenge arguments with structured reasoning in the Digital Agora.

Join & respond

Embed this claim

<iframe
  src="https://www.isonomia.app/embed/claim/0556f2435074361146313cba4fa7ed59c0e6fed007017137283abfbaf18e543a"
  width="600"
  height="280"
  frameborder="0"
  style="border: 1px solid #e5e7eb; border-radius: 8px;"
  title="Isonomia Claim"
  loading="lazy"
></iframe>

Copy and paste into any website or forum that supports HTML.